Citius Oncology, Inc. Common Stock
CTORCitius Oncology, Inc. (CTOR) is a biopharmaceutical company focused on developing targeted cancer therapies. The company aims to advance innovative treatments by leveraging immunology and oncology research to improve outcomes for cancer patients.
Company News
Citius Pharmaceuticals reported its first revenue of $3.9 million in Q1 2026 following the December 2025 launch of LYMPHIR by its majority-owned subsidiary Citius Oncology. The drug, approved for treating relapsed or refractory cutaneous T-cell lymphoma, has begun initial sales through a nationwide distributor network. The company raised $20.9 mi...
Citius Oncology reported its first revenue of $3.9 million following the successful December 2025 U.S. commercial launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma. The company established nationwide distribution infrastructure and deployed an AI-enabled commercial platform. Despite positive commercial progress, the c...
Citius Oncology closed a registered direct offering and private placement, raising approximately $18 million to support the commercial launch of LYMPHIR and for general corporate purposes.
Citius Oncology raised $18 million through a registered direct offering and private placement to support the commercial launch of LYMPHIR, a novel cancer immunotherapy for cutaneous T-cell lymphoma, with H.C. Wainwright & Co. acting as the exclusive placement agent.
Citius Oncology closed a $9.0 million registered direct offering and private placement, issuing 5,142,858 shares of common stock and accompanying warrants at $1.75 per share, with warrants exercisable at $1.84 per share.
